掲載種別：研究論文（学術雑誌）   出版者・発行元：European Respiratory Society (ERS)  

Background

Recurrence-, progression-, disease- and event-free survival are often selected as the primary end-points for trials assessing peri-operative systemic therapy for nonsmall cell lung cancer (NSCLC). As overall survival (OS) has increased, these surrogates, which we hereafter collectively term “recurrence-/progression-free survivals (RPFS)”, have become more attractive end-points.

Methods

This systematic review, without meta-analysis, was conducted in accordance with the guidelines established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (UMIN000052558). Electronic databases were searched on 11 October 2023. English-language articles presenting a randomised controlled trial assessing neoadjuvant and/or adjuvant systemic therapy for NSCLC were included. The main outcome was the weighted Spearman's rank correlation coefficient (r) between the hazard ratios (HRs) of OS (HRos) and RPFS (HRrpfs). The weight assigned to each study was determined using the inverse variance of the log HRos. Pathological subtype and driver mutations were not questioned.

Results

We identified 31 trials with a total of 15 776 patients. The weighted correlation coefficient was 0.86 based on the raw data from the 31 trials. After reciprocal duplication, the weighted correlation coefficient was 0.91 (p<0.001 for unweighted r). Subgroup analyses showed the correlation was 0.98 for trials with immune checkpoint inhibitors but was 0.54 for molecular targeted therapy

Conclusions

We hope that our data will justify the use of the HRs of recurrence-, progression-, disease- and event-free survival as primary end-points in peri-operative immune checkpoint inhibitor regimens for NSCLC.

DOI： 10.1183/16000617.0034-2025

researchmap

記述言語：英語   掲載種別：研究論文（学術雑誌）  

OBJECTIVE: Although Mycobacterium avium complex (MAC) lung disease has been shown to be associated with lung cancer and hematologic malignancies, there have been few studies of its relationships with other types of cancer. The aim of this study was to assess the effect that coexisting advanced extrapulmonary solid tumors have on the progression of MAC lung disease. METHODS: This was a retrospective study of patients diagnosed with MAC lung disease, on the basis of the American Thoracic Society (ATS) criteria, between October of 2005 and March of 2019. The patients were divided into three groups: those with advanced-stage cancer (A-SC group); those with early-stage cancer (E-SC group); and those without cancer (control group). Progression of MAC lung disease was defined as exacerbation seen on imaging. Patient characteristics and the time to progression were compared among the three groups. RESULTS: A total of 286 patients met the ATS diagnostic criteria for MAC lung disease, and 128 of those were excluded. Of the remaining 158 patients, 20 (7.0%) were in the A-SC group, 36 (12.6%) were in the E-SC group, and 102 (35.7%) were in the control group. The median time to progression in the A-SC, E-SC, and control groups was 432, 3,595, and 2,829 days, respectively (p < 0.01). A proportional hazards model showed that the significant predictors of MAC lung disease progression were advanced-stage cancer (hazard ratio [HR] = 6.096; 95% CI: 2.688-13.826; p < 0.01), cavitary lesions (HR = 2.750; 95% CI: 1.306-5.791; p < 0.01), and a high Nodule-Infiltration-Cavity-Ectasis score (HR = 1.046; 95% CI: 1.004-1.091; p = 0.033). CONCLUSIONS: A coexisting advanced extrapulmonary solid tumor could hasten the progression of MAC lung disease.

DOI： 10.36416/1806-3756/e20200520

PubMed

researchmap